|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...123124125126127128129130131132133...156157» |
- || Humira (adalimumab) / AbbVie
Trial completion: Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use (clinicaltrials.gov) - Apr 1, 2013
P3, N=32, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed
- Trial termination: Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II (clinicaltrials.gov) - Mar 31, 2013
P2, N=18, Terminated, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Active, not recruiting --> Completed Recruiting --> Terminated; Unusual high frequency of elevated liver function tests.
- Enrollment change: Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 31, 2013
P=N/A, N=106, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Terminated; Unusual high frequency of elevated liver function tests. N=210 --> 106
- Soliris (eculizumab) / AstraZeneca
Trial withdrawal: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab (clinicaltrials.gov) - Mar 28, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
N=210 --> 106 Recruiting --> Withdrawn
- Soliris (eculizumab) / AstraZeneca
Enrollment change: Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab (clinicaltrials.gov) - Mar 28, 2013
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Withdrawn N=10 --> 0
- || prednisone delayed-release tablet / Generic mfg.
New P3 trial: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 27, 2013
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
- ||| ultra-rapid-acting recombinant human insulin (BIOD-123) / Ipsen
Enrollment closed: A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog (clinicaltrials.gov) - Mar 27, 2013
P2, N=130, Active, not recruiting, Sponsor: Biodel
N=10 --> 0 Recruiting --> Active, not recruiting
- amiloride hydrochloride / Generic mfg.
Enrollment open: ACTION: Amiloride Clinical Trial In Optic Neuritis (clinicaltrials.gov) - Mar 25, 2013
P2, N=46, Recruiting, Sponsor: University of Oxford
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment open: NIDOCIGA: IgA Nephropathy, Lymphocyte Homing and IgA Class Switch (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=72, Recruiting, Sponsor: University Hospital, Limoges
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| inactivated VZV vaccine (V212) / Merck (MSD)
Trial completion: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) (clinicaltrials.gov) - Mar 25, 2013
P2, N=354, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Epratucyn (epratuzumab) / Gilead
Trial completion: Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Mar 25, 2013
P1/2, N=20, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tresiba (insulin degludec) / Novo Nordisk
Trial completion: A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine (clinicaltrials.gov) - Mar 25, 2013
P1, N=40, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Trial completion: Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis (clinicaltrials.gov) - Mar 25, 2013
P2, N=201, Completed, Sponsor: Tranzyme, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | dalfampridine / Generic mfg.
Enrollment closed: Dalfampridine for Imbalance in Multiple Sclerosis (clinicaltrials.gov) - Mar 24, 2013
P2, N=24, Active, not recruiting, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date, Combination therapy, Monotherapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 24, 2013
P4, N=261, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Feb 2011 --> Sep 2011
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 24, 2013
P3, N=378, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Feb 2011 --> Sep 2011 Active, not recruiting --> Completed
- Trial termination: Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy (clinicaltrials.gov) - Mar 22, 2013
P=N/A, N=5, Terminated, Sponsor: Centre Hospitalier Universitaire de N?mes
Active, not recruiting --> Completed Recruiting --> Terminated; Unable to find enough patients who accept randomization of surgical procedures.
- Enrollment change: Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy (clinicaltrials.gov) - Mar 22, 2013
P=N/A, N=5, Terminated, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Terminated; Unable to find enough patients who accept randomization of surgical procedures. N=150 --> 5
- |||||| blisibimod (A-623) / Anthera Pharma
Enrollment open: CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 21, 2013
P3, N=400, Recruiting, Sponsor: Anthera Pharmaceuticals
N=150 --> 5 Not yet recruiting --> Recruiting
- glatiramer acetate / Generic mfg.
Trial completion: GASWI: A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=60, Completed, Sponsor: University at Buffalo
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Trial completion: Comparing Tai Chi Chih and Relaxation Therapy in the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Mar 20, 2013
P2/3, N=100, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment change: Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP (clinicaltrials.gov) - Mar 20, 2013
P2, N=21, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Active, not recruiting --> Completed N=30 --> 21
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP (clinicaltrials.gov) - Mar 20, 2013
P2, N=21, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
N=30 --> 21 Recruiting --> Completed
- | Trial completion: Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate (clinicaltrials.gov) - Mar 19, 2013
P4, N=40, Completed, Sponsor: Brown, Theodore R., M.D., MPH
Recruiting --> Completed Recruiting --> Completed
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion: Glucocorticoid Treatment in Addison's Disease (clinicaltrials.gov) - Mar 18, 2013
P2/3, N=33, Completed, Sponsor: Haukeland University Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Mar 18, 2013
P3, N=200, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: Fructose and Glucose and TAS1R2 in Type 1 Diabetes (clinicaltrials.gov) - Mar 18, 2013
P=N/A, N=30, Recruiting, Sponsor: Universidade Federal do Rio de Janeiro
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment closed: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2013
P1, N=147, Active, not recruiting, Sponsor: Celltrion
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Trial completion: A Clinical Investigation of the Taperloc (clinicaltrials.gov) - Mar 18, 2013
P=N/A, N=98, Completed, Sponsor: Biomet Orthopedics, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Trial completion: A Clinical Investigation of the Balance (clinicaltrials.gov) - Mar 18, 2013
P=N/A, N=70, Completed, Sponsor: Biomet Orthopedics, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Combination therapy: An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=77, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=100 --> 77
- |||||| BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
Enrollment open: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 17, 2013
P3, N=306, Recruiting, Sponsor: Boehringer Ingelheim
N=100 --> 77 Ongoing --> Recruiting
- ||| tregalizumab (BT-061) - ADMA Biologics, T / Balance Therapeutics
Enrollment closed: Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX) (clinicaltrials.gov) - Mar 17, 2013
P2, N=176, Active, not recruiting, Sponsor: Biotest
Ongoing --> Recruiting Recruiting --> Active, not recruiting
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Combination therapy: An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=77, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| CH-4051 / Lundbeck
Trial completion, Monotherapy: MOTION: A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 17, 2013
P2, N=250, Completed, Sponsor: Chelsea Therapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=600, Not yet recruiting, Sponsor: University of Illinois at Chicago
Active, not recruiting --> Completed Initiation date: Sep 2012 --> Apr 2013
- ||| Trial initiation date: A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor ? (TNF?) in a General Hospital Setting in Korea (clinicaltrials.gov) - Mar 17, 2013
P4, N=1700, Completed, Sponsor: Janssen Korea, Ltd., Korea
Initiation date: Sep 2012 --> Apr 2013 Initiation date: Jun 2011 --> Dec 2011
- ||| decernotinib (VX-509) / Vertex
Enrollment closed: 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate (clinicaltrials.gov) - Mar 17, 2013
P2, N=350, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Initiation date: Jun 2011 --> Dec 2011 Recruiting --> Active, not recruiting
- |||| Trial completion: A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor ? (TNF?) in a General Hospital Setting in Korea (clinicaltrials.gov) - Mar 17, 2013
P4, N=1700, Completed, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog (clinicaltrials.gov) - Mar 14, 2013
P1, N=43, Completed, Sponsor: Novo Nordisk
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | BIOD-238 / Ipsen, BIOD-250 / Ipsen
New P1 trial: Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog (clinicaltrials.gov) - Mar 13, 2013
P1, N=12, Completed, Sponsor: Biodel
- Trial completion: DMB: Bone Health in Type 1 Diabetes (clinicaltrials.gov) - Mar 13, 2013
P=N/A, N=60, Completed, Sponsor: Creighton University
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Enrollment closed, Patient reported outcomes: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (clinicaltrials.gov) - Mar 12, 2013
P4, N=313, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- Tekturna (aliskiren) / PDL
Trial withdrawal: Aliskiren in Patients With Idiopathic Membranous Nephropathy (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Completed --> Withdrawn
- Tekturna (aliskiren) / PDL
Enrollment change: Aliskiren in Patients With Idiopathic Membranous Nephropathy (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Completed --> Withdrawn N=10 --> 0
- | Enrollment closed: The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device (clinicaltrials.gov) - Mar 11, 2013
P4, N=40, Active, not recruiting, Sponsor: Insuline Medical Ltd.
N=10 --> 0 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, MRI: Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Mar 10, 2013
P2, N=60, Completed, Sponsor: Gaylis, Norman B., M.D.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Trial termination: Initial Treatment of Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Mar 10, 2013
P3, N=8, Terminated, Sponsor: New England Research Institutes
Active, not recruiting --> Completed Recruiting --> Terminated; The study was closed due to accrual futility there were only a total of 8 subjects enrolled.
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies (clinicaltrials.gov) - Mar 10, 2013
P3, N=2068, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated; The study was closed due to accrual futility there were only a total of 8 subjects enrolled. Initiation date: Aug 1929 --> Sep 2005
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Enrollment change: Initial Treatment of Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Mar 10, 2013
P3, N=8, Terminated, Sponsor: New England Research Institutes
Initiation date: Aug 1929 --> Sep 2005 N=140 --> 8